People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Editas Medicine, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.9B | 2015 |
| Magenta Therapeutics, Inc. | — | Biotechnology | Series C | $116.0M | $2.1B | 2016 |
| Foundation Medicine, Inc. | — | Biotechnology | Series C | $115.5M | $2.3B | 2010 |
| Tango Therapeutics, Inc. | — | Pharmaceuticals | Series C | $95.0M | $83.2M | 2023 |
| Blueprint Medicines Corp | — | Biotechnology | Series C | $73.2M | $2.0B | 2014 |
| Celsius Therapeutics, Inc. | — | Pharma | Series C | $48.0M | $1.7B | 2018 |
Alexis Borisy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alexis Borisy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Bruce Booth | 1 | 12 |
| Mark Levin | 1 | 9 |
| John Davis | 1 | 7 |
| Robert Tepper | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| Andrew Hack | 1 | 5 |
| JASON GARDNER | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Blake Byers | 1 | 5 |
| Thomas Daniel | 1 | 4 |
| Alexandra Glucksmann | 1 | 4 |
| Katrine Bosley | 1 | 4 |
| Vic Myer | 1 | 3 |
| Jeffrey Albers | 1 | 3 |
| Boris Nikolic | 1 | 3 |
| Kyle Kuvalanka | 1 | 3 |
| Daniella Beckman | 1 | 2 |
| Robert W. Hesslein | 1 | 2 |
| Lesley Ann Calhoun | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.